Published online 27 May 2008
Haematologica, Vol 93, Issue 7, 1101-1103 doi:10.3324/haematol.12373
Copyright © 2008 by Ferrata Storti Foundation

This Article Full Text (PDF) Jonsson et al. - Supplementary Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jönsson, S. Articles by Wadenvik, H. Search for Related Content PubMed PubMed Citation Articles by Jönsson, S. Articles by Wadenvik, H.

Chronic Myeloid Leukemia

Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia

Sofia Jönsson¹, Bob Olsson¹, Claes Ohlsson², Mattias Lorentzon², Dan Mellström², Hans Wadenvik¹

¹ Haematology Section, Department of Internal Medicine, Gothenburg University, Gothenburg
² Center for Bone Research, Department of Internal Medicine, Gothenburg University, Gothenburg, Sweden

Correspondence: Sofia Jönsson, M.D., Haematology Section, Department of Internal Medicine, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden. Phone: international +46.31.3227782. Fax: international +46.31.416488. E-mail:sofia.jonsson{at}vgregion.se

Key words: imatinib, calcium, phosphate, chronic myelogenous leukemia, bone mineral density.

Imatinib mesylate (Glivec^®, Gleevec^TM, Novartis International AG) and the second generation ABL tyrosine kinase inhibitors have markedly improved the outcome of patients with chronic myeloid leukemia (CML). More patients are receiving treatment with these inhibitors for prolonged periods of time and experience with imatinib now exceeds five years. The immediate side effects are usually mild and manageable. There have been recent reports on the long-term side effects associated with prolonged use of imatinib.^1–3 Berman and coworkers found that imatinib treated patients had hypophosphatemia, lower osteocalcin levels and higher parathyroid hormone levels.² Subsequent studies confirmed the observation of hypophosphatemia in patients receiving imatinib.^4–8 The authors concluded that imatinib may affect bone remodeling and if left untreated, chronic hypophosphatemia may result in impaired bone mineralization, rickets, and osteomalacia.²

We, therefore, investigated bone mineral density (BMD) in imatinib treated CML patients and healthy controls. All imatinib treated CML patients at Sahlgrenska University Hospital were identified of whom 17 fulfilled the study inclusion criteria: (i) imatinib treatment duration 24 months, and (ii) first chronic phase of the disease with complete cytogenetic remission. The inclusion criteria were set to minimize the confounding effect of leukemia and to allow time for a possible bone remodeling effect of imatinib to take place. Sex and aged matched healthy individuals served as controls (Table 1). The imatinib dose was 400 mg per day. The treatment duration was 50±19 months (range 24–73). The study was approved by the local research ethics committee. Details of design and methods are available as an online supplement.

View this table: [in this window] [in a new window] [Download PPT slide]

Table 1. Blood counts, serum chemistry and bone related variables in imatinib treated chronic myeloid leukemia patients (n=17), and age and sex matched healthy controls (n=17). The results are given as mean ± SD.

The CML patients had significantly lower levels of calcium, ionized calcium, phosphate and magnesium in serum compared with controls (Table 1). Two out of 17 patients had serum ionized calcium below the reference range (1.18–1.31 mmol/L), 2 out of 17 patients had serum phosphate below the reference range (0.7–1.6 mmol/L) while none of the patients had serum magnesium below the reference range (0.7–0.95 mmol/L). The excretion of calcium in the urine was also found to be significantly lower in the imatinib treated patients (Table 1). The markers of bone turnover, osteocalcin and bone-specific alkaline phosphatase were significantly lower in patients compared with controls, whereas the marker of bone resorption carboxyterminal cross-linked telopeptide of type I collagen was unchanged (Table 1).

Our data confirm and extend those of Berman and coworkers despite differences in the patient and control design.² Berman et al. reported that imatinib treated CML and gastrointestinal stromal tumor patients with hypophosphatemia had a lower osteocalcin level, higher parathyroid hormone level and were treated with a higher imatinib dose (median 600 mg) than patients with a normal phosphate level. These findings were explained by an imatinib induced inhibition of bone turnover, which in turn, triggered a secondary hyperparathyroidism in an attempt to maintain calcium homeostasis. The authors raised concerns about an imatinib induced osteomalacia and suggested phosphate replacement therapy. In contrast to the hypothesized imatinib induced osteomalacia, we found that our imatinib treated CML patients had significantly higher areal BMD of the lumbar spine (+12%) and total hip bone (+12%) compared with controls (Table 2). Even compared with the standard reference, the patients had higher BMD than could be expected for age and gender. The patients’ T-score value was 0.07 and 0.38 for the total hip bone and lumbar spine respectively (Table 2). The patients’ Z-score value was 0.46 and 0.57 for total hip bone and lumbar spine (L1–4) respectively. A significant relationship was also observed between the imatinib treatment duration and areal BMD of the lumbar spine (L1–L4) (Spearman’s =0.49, p=0.046). Similarly, for both radius and tibia the imatinib treated CML patients had significantly higher cortical volumetric BMDs than the controls. No difference was seen in trabecular volumetric BMD of either radius or tibia. The cortical cross-sectional area was also similar in the two groups (Table 2).

View this table: [in this window] [in a new window] [Download PPT slide]

Table 2. BMD measurements in imatinib treated chronic myeloid leukemia patients (n=17) and controls (n=17).

Our results are also in line with previous in vitro studies and animal models. Osteoblasts are known to derive from mesenchymal stem cells, while osteoclasts are multinucleated giant cells of hematopoietic origin in the monocytic lineage. Both are targeted by imatinib and it has been shown that imatinib promotes osteoblast differentiation and inhibits osteoclastogenesis, presumably through its action on the colony-stimulating factor 1 receptor (C-FMS) and platelet derived growth factor receptor (PDGFR).^9,10

Overall, biochemical findings suggest a suppressed bone turnover and the increased BMD indicates that bone formation and resorption are affected unequally. We suggest that imatinib uncouples bone formation from bone resorption in favor of the former, disturbing bone homeostasis and leading to a net increase in bone mineral density.

This is further supported by a recent study by Fitteri et al.,¹¹ who reported an increased trabecular bone volume in imatinib treated patients. In contrast to our study, they did not analyze the bone mineralization, but measured the trabecular bone volume on decalcified iliac crest biopsies obtained before and during imatinib treatment. Therefore, bone mineralization, the most important measure of osteopenia, was not addressed.

The present report is the first demonstrating altered calcium and phosphate metabolism in imatinib-treated CML patients, concomitant with an increased cortical bone mineralization. Our study alleviates previous concerns about an accelerated osteomalacia, and measures to prevent this hypothesized long-term side effect seem unnecessary and might even be harmful.^2,12

If imatinib is shown to suppress bone resorption without decreasing the bone quality, tyrosine kinase inhibitors could be novel antiosteolytic agents in skeletal disorders.

 
Funding: the study was supported by grants from the Swedish Research Council (project K2006-71X-11630-07B and project 529-2004-6512), FoU Västra Götaland, the Swedish Society for Medical Research, "JK-foundation" Sahlgrenska University Hospital, "Volvo Assar Gabrielssons foundation", the Foundations of the National Board of Health and Welfare, the Åke Wiberg Foundation, the Jeansson Foundation, the Tore Nilsson Foundation for Medical Research and the Magnus Bergvall Foundation.

TOP References

 

1. Appel S, Balabanov S, Brummendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 2005;23:1082-8.[CrossRef][Web of Science][Medline]
2. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-13.[Abstract/Free Full Text]
3. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16.[CrossRef][Web of Science][Medline]
4. Grey A, O’Sullivan S, Reid IR, Browett P. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 2006;355:2494-5.[Free Full Text]
5. Joensuu H, Reichardt P. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006;355:628-9.[Web of Science][Medline]
6. Osorio S, Noblejas AG, Duran A, Steegmann JL. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol 2007;82:394-5.[CrossRef][Web of Science][Medline]
7. Owen S, Hatfield A, Letvak L. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006;355:627-9.[Free Full Text]
8. Zekri JM, Robinson MH, Woll PJ. Relative hypocalcaemia and muscle cramps in patients receiving imatinib for gastrointestinal stromal tumour. Sarcoma 2006;2006:48948.[Medline]
9. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005;105:3127-32.[Abstract/Free Full Text]
10. O’Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007;22:1679-89.[CrossRef][Web of Science][Medline]
11. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, et al. Long term imatinib therapy promotes bone formation in CML patients. Blood 2008;111:2538-47.[Abstract/Free Full Text]
12. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007;357:258-65.[Free Full Text]

This article has been cited by other articles:

				K. Vandyke, S. Fitter, A. L. Dewar, T. P. Hughes, and A. C. W. Zannettino Dysregulation of bone remodeling by imatinib mesylate Blood, January 28, 2010; 115(4): 766 - 774. [Abstract] [Full Text] [PDF]

				H. Schmid, B. A.S. Jaeger, J. Lohse, and M. Suttorp Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib Haematologica, August 1, 2009; 94(8): 1177 - 1179. [Full Text] [PDF]

This Article Full Text (PDF) Jonsson et al. - Supplementary Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jönsson, S. Articles by Wadenvik, H. Search for Related Content PubMed PubMed Citation Articles by Jönsson, S. Articles by Wadenvik, H.